The Study Will Evaluate the Efficacy of AZD5423 in Patients With Mild Asthma Challenged With an Inhaled Allergen

• Status: Completed
• Trial end date: 2011-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the efficacy of AZD5423 in patients with mild asthma challenged with an inhaled allergen.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Budesonide

Criteria

Inclusion Criteria:

• 18-60 years of age

• Pre-bronchodilatory FEV1 ≥70% of predicted normal allergic asthmatic with a history of episodic wheeze

• Positive allergen induced early and late airway bronchoconstriction showing ≥ 20% fall in FEV1 for the early and ≥ 15% for the late response

• Positive skin prick test to common aeroallergens

Exclusion Criteria:

• Any clinically significant disease or disorder

• Any clinically relevant abnormal finding at screening examinations

• Smoker or ex-smoker who has stopped smoking < 12 months prior to study start

• Worsening of asthma or respiratory infection within 6 weeks from visit 1

• Allergen-specific immunotherapy within 6 months prior to visit 1